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ABSTRACT
The treatment of locally advanced rectal cancer (LARC) has seen major advances over the past 3 decades, with multimodality
treatment now standard of care. Combining surgical resection with radiotherapy and/or chemotherapy can reduce local recurrence
from around 20% to approximately 5%. Despite improvements in local control, distant recurrence and subsequent survival rates
have not changed. Immune checkpoint inhibitors have improved patient outcomes in several solid tumor types in the
neoadjuvant, adjuvant, and advanced disease setting; however, in colorectal cancer, most clinical trials have been performed in the
metastatic setting and the benefits confined to microsatellite instability–high tumors. In this article, we review the current
preclinical and clinical evidence for using immune checkpoint inhibition in the treatment of LARC and discuss the rationale for
specifically exploring the use of this therapy in the neoadjuvant setting. We summarize and discuss relevant clinical trials that are
currently in setup and recruiting to test this treatment strategy and reflect on unanswered questions that still need to be addressed
within future research efforts.
Keywords: neoplasm, rectum, radiotherapy, chemotherapy, immunotherapy, immunology, clinical trials, immune checkpoint
inhibitor, colorectal cancer
INTRODUCTION
Colorectal cancer (CRC) is the third most common
cancer globally,[1] and approximately one-third of CRC
tumors are located in the rectum.[2] Nearly three-quarters
of patients diagnosed with rectal cancer present with
localized, nonmetastatic disease.[2] Although surgery alone
for early-stage tumors is often curative, in locally advanced
disease, this approach has historically resulted in unac-
ceptably high rates of local recurrence (16% in stage II and
29% in stage III).[3] Consequently, neoadjuvant treatment
is recommended before surgery, based on high-quality
magnetic resonance imaging (MRI) staging,[4,5] with the
aim of reducing local recurrence rates to approximately
5%.[6] Although very effective from an oncological
standpoint, the functional and psychological long-term
sequelae of combined therapy incorporating radical
surgery (6 permanent stoma) are well recognized.[7]
The use of multimodality neoadjuvant treatment for
locally advanced rectal cancer (LARC) has resulted in
three primary response patterns: pathological complete
response (pCR) with rates of approximately 14%, some
tumor regression in approximately 65%, and no macro-
scopic regression in approximately 20% of patients.[8–10]
Thus, in a small proportion of well-selected patients who
achieve complete clinical response (cCR), treatment de-
escalation and ‘‘organ preservation’’ are possible, and
these patients can potentially avoid the risks and
sequelae of surgery.[11,12] Published series have demon-
strated similar disease free survival (DFS) and overall
survival (OS) for patients who have organ preservation
compared with those who undergo surgery,[13,14] with 3-
year colostomy-free survival of up to 74%.[14] For
patients who respond poorly to neoadjuvant treatment,
mortality is driven by distant relapse and up to 30% will
die from distant disease.[15] Therefore, increasing the
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proportion of patients who achieve cCR and reducing
distant recurrence have both been identified as top
research priorities.[16]
Over the past 2 decades, an improved understanding
of the role of the immune system in response to
malignant cells has spurred the development of targeted
therapies to shape this response for therapeutic bene-
fit.[17] Naturally occurring checkpoint molecules within
the host immune system, for example PD-1 and CTLA-4,
exist, which prevent immune overactivation. These T-
cell surface proteins, which bind to PDL-1 on antigen-
presenting cells (APCs) and tumor cells (PD-1), or B7-1
and B7-2 on APCs, downregulate immune activation.[18]
Therapies that inhibit the binding of these checkpoint
molecules therefore increase T-cell–mediated antitumor
immunity. In clinical practice, immune checkpoint
inhibitors (ICIs) have been particularly successful in
tumor types such as melanoma, renal cancer, and non–
small-cell lung cancer (NSCLC); however, for other solid
organ tumors their use has lagged.[19]
In CRC, extremely encouraging response rates with
immunotherapy treatment have been observed in a
select group of patients, predicted in a large part on the
presence of microsatellite instability (MSI) within the
tumor. Errors in DNA base pairing introduced during cell
replication are usually repaired via the mismatch repair
(MMR) system and microsatellites are short DNA
sequences that are markers of deficient MMR. Disease
with MSI is defined by high mutational burden and very
low or absent copy number variation, whereas microsat-
ellite stable (MSS) disease is characterized by low
mutation burden and high copy number variation.[20]
MSI-High (MSI-H) disease is enriched in earlier CRC
disease stages with rates of 10 to 15% for stage II-III,[20]
falling to approximately 4% for patients with stage IV
CRC.[21] Overall, MSI confers improved prognosis in
nonmetastatic CRC,[22] but there is a trend to worse
prognosis for those with stage IV disease.[23] An im-
proved understanding of processes underlying MSI
response/nonresponse, as well as identification of addi-
tional biomarkers, may be the key to unlocking the
potential for more widespread treatment of CRC with
immune checkpoint therapy by potentiating this bene-
ficial biological effect in MSS CRC. This is particularly
true in rectal cancer in which MSI has a low preva-
lence.[24]
This concise review aims to explain the rationale for
using immune checkpoint inhibition as part of the
neoadjuvant management of LARC. We first describe the
current landscape of neoadjuvant therapy for LARC,
followed by the clinical evidence for immune checkpoint
inhibition in CRC and the biological rationale under-
pinning the combination of immune checkpoint inhib-
itors with treatments such as radiotherapy and
chemotherapy. Finally, we summarize current clinical
studies that are assessing this strategy and reflect on
unanswered gaps in knowledge that still need to be
addressed.
CONTEMPORARY NEOADJUVANT
TREATMENT STRATEGIES FOR LOCALLY
ADVANCED RECTAL CANCER
There are two principal radiotherapy strategies in
widespread use for LARC: a short-course radiotherapy
(SCRT) regimen (25 Gy in 5 fractions) and a long-course
chemoradiotherapy (LCRT) regimen (45.0–50.4 Gy in
25–28 fractions) with concurrent fluoropyrimidine
chemotherapy[4,5] (Fig. 1). Attempts to intensify neo-
adjuvant radiation sensitivity using additional or
alternative cytotoxics, such as oxaliplatin,[25–30] have
had inconsistent results and no additional agents are
widely used concomitantly with radiotherapy as stan-
dard of care. The recently reported toxicity results from
the phase III ARISTOTLE trial, which has tested LCRT
intensification with irinotecan, have shown a modest
increase in G3 toxicity, but with no significant differ-
ence in pCR rates (20.2 versus 17.4%; p ¼ 0.45)[31] and
the full primary outcome of DFS results from this trial
are awaited.
Traditionally, SCRT treatment was followed immedi-
ately (within 1 week) by surgical resection; however, this
approach had inferior tumor downstaging outcomes
compared with LCRT,[9,32] albeit similar local control. It
has since been demonstrated that leaving a gap of 4 to 8
weeks before surgery (SCRT-delay) offers equivalent
oncological outcomes to LCRT and delay, or SCRT and
immediate surgery, with less postoperative morbidity.[33]
The SCRT-delay strategy also achieves higher rates of
complete response not usually appreciated with SCRT-
immediate surgery (pCR 11.8 versus 1.7%).[33] LCRT has
traditionally been followed by surgery at approximately
6 weeks, as this interval demonstrated improved tumor
downstaging compared with an interval of 2 weeks. [34]
Despite data indicating that a longer interval from LCRT
to surgery does not affect outcomes, [35,36] there is now a
large evidence base to suggest that lengthening the
interval between LCRT completion and surgery may
enhance response. [8,37–41] In a recent analysis of pooled
clinical trial data, Gambacorta et al[42] demonstrated that
cumulative pCR rates were higher in a group of patients
with a median interval of 6 weeks or more (18.8%)
compared with those with an interval of less than 6
weeks (11.6%; p , 0.01), with no significant difference
between DFS or OS. There was a significant correlation
between pCR and time from LCRT to surgery as a
continuous variable (p , 0.01, linear regression coeffi-
cient 2.24) with a significant increase in cumulative pCR
rate between week 4 (1%) and 11 (13%), plateauing at
week 16 (pCR rate of 14%). Landmark studies in the
neoadjuvant management of LARC are summarized in
Figure 1. [9,32,33,37,43–58]
In addition to the maturation of tumor regression,
exploiting the gap between completing SCRT/LCRT and
subsequent resection is attractive for a number of
reasons. Clinical studies administering adjuvant chemo-
therapy for rectal cancer have been negative,[59–61] closed
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early due to poor recruitment,[62,63] or were underpow-
ered to define the benefit of adjuvant chemotherapy in
patients with LARC treated with radiation.[64] Neo-
adjuvant chemotherapy appears to have better compli-
ance,[65,66] and earlier introduction of systemic therapy
may impact on distant relapse. Last, there is the
opportunity to further downstage the in situ disease
and better understand the tumor biology. The results of a
recent meta-analysis of outcomes from trials assessing
total neoadjuvant strategies are detailed elsewhere (n ¼
28 studies).[67] In summary, this study showed the
average pCR achieved with the addition of systemic
chemotherapy to LCRT across all included studies was
22.4% and this was increased by 39% (p ¼ 0.01)
compared with comparative studies (n¼ 10) using LCRT
alone.
Adding FOLFOX (5-fluorouracil and oxaliplatin) che-
motherapy sequentially with LCRT produces encourag-
ing pCR rates compared with LCRT alone,[38,68] and 2
randomized phase II trials have indicated that the
Figure 1.—Landmark studies in the treatment
of locally advanced rectal cancer. Asterisk (*)
indicates awaiting full results. AIO: Arbesits-
gemeinschaft Internistische Onkologie; CA-
POX: capecitabine and oxaliplatin; CRM:
circumferential resection margin; CSS: cancer-
specific survival; DFS: disease-free survival;
EMVI: extramural vascular invasion; EORTC:
European Organisation for Research and
Treatment of Cancer; FFCD: Federation Fran-
cophone de Cancerologie; FOLFOX: 5-fluoro-
uracil and oxaliplatin; FU: fluorouracil; LCRT:
long-course chemoradiation; MFS: metastasis-
free survival; MOF: 5-fluorouracil, vincristine
and semustine; MRC: Medical Research
Council; NCCTG: North Central Cancer
Treatment Group; NCIC-CTG: National Can-
cer Institute of Canada Clinical Trials Group;
NSABP: National Surgical Adjuvant Breast and
Bowel Project; OPRA: organ preservation in
rectal adenocarcinoma; OS: overall survival;
OX: oxaliplatin; pCR: pathological complete
response; RAPIDO: rectal cancer and preoper-
ative induction therapy followed by dedicated
operation; RT: radiotherapy; SCRT: short
course radiotherapy; TME: total mesorectal
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sequencing of neoadjuvant treatments may be impor-
tant.[54,57] Specifically, a German phase II trial (CAO/
ARO/AIO-12) that compared giving chemotherapy be-
fore LCRT versus after radiotherapy, showed better
treatment compliance and pCR rates for the latter
approach.[54] The preliminary results from the Organ
Preservation in Rectal Adenocarcinoma (OPRA) trial have
shown than offering consolidation chemotherapy after
LCRT improves the 3-year organ preservation rate (59%;
95% CI 50–69%; versus 43%; 95% CI 35–54%; log rank p
¼ 0.007) compared with induction chemotherapy before
LCRT.[57] For SCRT, radiotherapy followed by three cycles
of FOLFOX produces similar response rates to oxalipla-
tin-based LCRT for cT3 and cT4 tumors.[69]
Even more encouraging are the results from a recent
Dutch/Scandinavian Rectal cancer And Preoperative
Induction therapy followed by Dedicated Operation
(RAPIDO) trial, which demonstrated that SCRT followed
by chemotherapy (18 weeks of CAPOX [capecitabine
plus oxaliplatin]) before surgery improved disease-related
treatment failure and pCR rates compared with LCRT
with optional adjuvant chemotherapy (standard
arm).[58,70,71] Importantly, this is one of the first trials
to achieve improvement in distant recurrence rates, with
a reduction of almost 7% for the experimental arm
(hazard ratio [HR] 0.69; 0.53–0.89; p ¼ 0.04). A similar
finding in improving the rate of distant metastases was
reported in the PRODIGE-23 trial,[55] which compared
the addition of a triple chemotherapy combination
(FOLFIRINOX: irinotecan 150 mg/m2 day 1 (D1),
oxaliplatin 85 mg/m2 D1, 5-fluorouracil 400 mg/m2
bolus plus 2400 mg/m2 infusion over 46 hours) with
LCRT in the neoadjuvant setting to LCRT alone, with
high compliance rates with chemotherapy (. 90%) and
radiotherapy (. 98%) being maintained, despite the
intensive approach. In RAPIDO there was similarly good
compliance when chemotherapy was delivered preoper-
atively (and improved compared with postoperatively).
Although maturing data will be further interrogated,
these data continue to support the argument that using
systemic treatment in the neoadjuvant setting, rather
than postoperatively, is beneficial when used with SCRT
or LCRT.[58,70,71]
Other systemic anticancer agents have been trialed in
this space but with minimal success. For example, the
multicenter phase II AVACROSS study added anti–
vascular endothelial growth factor (bevacizumab) thera-
py to oxaliplatin-based chemotherapy followed by
LCRT.[72] Although feasible, with an encouraging pCR
rate of 36% (95% CI 22.3%–51.3%), postoperative
complications were unexpectedly high, with two deaths
(4%), five anastomotic leaks (11%), and 11 patients
requiring second operations (23%). The addition of
epidermal growth factor receptor–directed therapy (ce-
tuximab)[73,74] also failed to meet pre-specified improve-
ments in pCR-related endpoints. The outcomes from the
parallel arm phase II platform trial NRG-GI002, which is
testing the addition of radiosensitizers to neoadjuvant
radiation as part of a total neoadjuvant approach, are
eagerly awaited.[75] A summary of the treatments used
and the pCR rates attained from the trials investigating
intensification of neoadjuvant treatment is presented in
Table 1.
Despite the limited success of targeted agents, the
underlying clinical rationale for treatment intensifica-
tion in the neoadjuvant setting for patients with LARC
remains. For example, in the RAPIDO trial, despite an
almost doubling of pCR rates in the experimental arm,
approximately 10% of patients in both arms had an R1/2
resection, and despite the reduction in distant relapse,
more than a fifth of patients developed distant meta-
static disease. This underscores an ongoing need to find
treatments that improve downstaging and decrease
systemic relapse. Biomarkers to identify patients who
are likely to be poor responders to radiation and
cytotoxic chemotherapy alone are particularly pressing.
The molecular landscape of CRC suggests that immuno-
modulation with ICIs is a logical next step.
CURRENT ROLE OF CHECKPOINT
INHIBITION IMMUNOTHERAPY IN
COLORECTAL CANCER
Until recently, documented responses to ICIs have
largely been confined to colorectal tumors with deficien-
cy in MMR. The MMR status of colorectal tumors can be
tested using DNA-based methods, which look for the
number of microsatellite markers (2–5: MSI-H, 1: MSI-
Low [MSI-L], or 0: MSS), or immunohistochemistry can
be used to look for deficiency in one of the MMR
proteins (MLH-1, MSH-2, MSH-6, PMS-2). Tumors dis-
playing loss of MMR are known as dMMR and are
considered MSI-H, and those without loss of these
proteins are known as MMR proficient (pMMR) and are
considered MSI-L or MSS. [76] One of the reasons
underpinning impressive responses of dMMR tumors to
immunotherapy relates to the high mutational burden
in MSI-H tumors, which leads to numerous tumor
neoantigens that are recognized and targeted by the
host immune system, reflected by high levels of tumor-
infiltrating lymphocytes (TILs).[77] The marked differenc-
es in tumor responses based on MMR status, in CRC and
other cancer types, led to the tumor agnostic US Food
and Drug Administration approval of immunotherapy
for any MSI-H cancers.[78]
Several trials have demonstrated extremely encourag-
ing response rates to immune checkpoint inhibition in
patients with metastatic dMMR CRC, even those who
were heavily pretreated (Table 2).[79–86] Moving treat-
ment into the first-line setting has improved responses
and using doublet immunotherapy treatment has in-
creased response rates even further. For example, recent
results from the Checkmate-142 trial reported an
objective response rate of 69% in the first-line setting
using dual-checkpoint inhibition for patients with
dMMR CRC.
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Table 1.—Summary of pathological complete response rates
Trial or




Neoadjuvant Treatment pCR (%)
Lyon R90–01[34] 1999 Randomized trial 201 Radiotherapy with surgery after 2
weeks vs radiotherapy with
surgery after 6–8 weeks
pCR not reported
Stein[35] 2003 Prospective cohort 40 LCRT with irinotecan and 5-
fluorouracil. Group A: Surgery 4–8
weeks post LCRT. Group B:
Surgery 10–14 weeks post LCRT.
21% (4–8 weeks)
14% (10–14 weeks), p ¼ 0.97
CAO/ARO/AI0–
94[47]
2004 Phase III RCT 823 Preoperative vs postoperative LCRT 9% in preoperative LCRT arm
Polish Trial
(Bujko)[9]
2006 Phase III RCT 312 Preoperative SCRT vs LCRT 0.7% (SCRT)




132 LCRT followed by surgery at 7 weeks
or less vs . 7 weeks
17% (7 weeks or less)
35% (. 7 weeks), p ¼ 0.03
ACCORD-12/0405-
Prodige 2[25]
2010 Phase III RCT 598 LCRT vs LCRT with oxaliplatin 13.9% (LCRT)
19.2% (LCRT with oxaliplatin), p ¼
0.09
Kim[74] 2010 Single-arm phase II
trial
40 LCRT with concurrent capecitabine,
cetuximab and irinotecan
23.10%
GCR-3[65] 2010 Phase II
randomized trial




14% (preoperative), p ¼ 0.94
STAR-01[29] 2011 Phase III RCT 747 LCRT vs LCRT with oxaliplatin 16% both arms
AVACROSS[74] 2011 Phase II single arm
trial
47 Induction XELOX and bevacizumab




TROG 01.04[32] 2012 Phase III RCT 326 Preoperative SCRT vs LCRT 15% (LCRT)
1% (SCRT) (Significance not reported)
CAO/ARO/A10–
04[28]
2012 Phase III RCT 1236 LCRT with adjuvant 5-fluorouracil vs
LCRT with concomitant and
adjuvant FOLFOX
13% (LCRT þ adjuvant 5-fluorouarcil)
17% (LCRT with FOLFOX), p ¼ 0.038
EXPERT-C[73] 2012 Randomized phase
II trial
165 Induction CAPOX followed by LCRT




11% (CAPOX-C), p ¼ 1.0
Sloothaak[39] 2013 Retrospective
cohort study
1593 LCRT followed by surgery at , 13
weeks, 13–14 weeks, 15–16 weeks,
. 16 weeks after the start of LCRT
10.3% (, 13 weeks)
13.1% (13–14 weeks)
18.0% (15–16 weeks)
11.0% (. 16 weeks), p ¼ 0.013
Probst[8] 2015 Retrospective
cohort study
17,255 Exact treatment unknown. Time
from LCRT to surgery , 6 weeks,
6–8 weeks or . 8 weeks.
8.7% (, 8 weeks)
11.7% (6–8 weeks)
13.2% (. 8 weeks), p , 0.001
Garcia-Aguilar[38] 2015 Phase III RCT 259 LCRT with surgery at 6–8 weeks vs
LCRT þ 2 3 mFOLFOX6 vs LCRT
þ 4 3 mFOLFOX6 vs LCRT þ 6 3
mFOLFOX6
18% (LCRT alone)
25% (LCRT þ 2 mFOLFOX6)
30% (LCRT þ 4 mFOLFOX6)
38% (LCRT þ 6 mFOLFOX6), p ¼
0.0036






PETACC-6[26] 2016 Phase III RCT 1094 LCRT with capecitabine adjuvant
chemotherapy vs LCRT with
neoadjuvant and adjuvant CAPOX
pCR not reported
GRECCAR-6[36] 2016 Phase III RCT 265 LCRT followed by surgery at 7 vs 11
weeks
15% (7 week arm)
17.4% (11 week arm), p ¼ 0.5983
Polish 2 Trial
(Bujko) [53]
2016 Phase III RCT 541 SCRT þ FOLFOXx3 (Group A) vs
LCRT w FU/OX þ delay (Group B)
16% (Group A)
12% (Group B), p ¼ 0.17
Stockholm III[33] 2017 Phase III RCT 840 overall trial,
697 for pCR
substudy
SCRT vs SCRT þ delay vs LCRT þ
delay
0.3% (SCRT)
10.4% (SCRT þ delay)
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Although these responses in both treatment naı̈ve and
heavily pretreated patients with metastatic dMMR CRC
are exciting, approximately 95% of patients with
metastatic CRC have pMMR disease. Traditionally,
responses to ICIs in patients with metastatic CRC
unselected for MMR status have been very low (,
10%),[19,87–90] and the proposed mechanisms of resis-
tance of pMMR colorectal tumors to ICIs are discussed
elsewhere.[91] Nevertheless, some encouraging data have
recently been presented in abstract form from a trial that
recruited patients with pMMR CRC (Table 2).[85,92]
Patients with heavily pretreated metastatic CRC (n ¼
179) were randomized to receive either a combination of
durvalumab (anti-PDL-1) 1500 mg 4 weekly with
tremelimumab (anti-CTLA 4) 75 mg on day 1, or best
supportive care. Patients in the former group survived
longer compared with the control arm (6.6 months
median OS versus 4.1 months, p¼0.07, HR 0.72, 95% CI
0.54–0.97). In patients with pMMR tumors, the HR for
death was 0.66 (90% CI 0.48–0.89; p ¼ 0.02) and those
with a tumor mutational burden achieved significantly
longer survival when treated with immunotherapy
compared with best supportive care alone (median OS
5.5 versus 3.0 months; p¼ 0.004). The results of this trial
show that using combination treatment is one way in
which resistance of pMMR disease to ICIs may be
overcome.
Another strategy for overcoming this resistance is to
use immunotherapy earlier in the disease trajectory.
Recently published evidence from an early-phase trial
(NICHE NCT03026140) in the neoadjuvant setting in
colon cancer, has shown improved response rates to
immunotherapy compared with those previously seen
for metastatic patients, and in particular for those with
pMMR disease. Patients with dMMR and pMMR colon
cancer were treated with concurrent anti-PD1 and anti-
CTLA4 therapy.[86] All of those with dMMR disease
displayed a pathological response, but, encouragingly, so
did 27% (95% exact CI 8%–55%) of those with pMMR
disease (Table 2). Although provocative, these data
require validation in a larger cohort, but certainly
provide optimism regarding the benefit that may be
gained from using immunotherapy to treat CRCs with
traditionally resistant molecular profiles. The use of
immunotherapy both for patients with pMMR and those
with dMMR CRC is an area of intense interest, and a
contemporary list of ongoing clinical trials is available
elsewhere.[93]
RATIONALE FOR USE OF IMMUNOTHERAPY
AS A NEOADJUVANT STRATEGY FOR
RECTAL CANCER
There are important distinctions between the meta-
static and neoadjuvant setting that provide a strong
Table 1.—Continued
Trial or




Neoadjuvant Treatment pCR (%)
Cercek[66] 2018 Retrospective
cohort study
628 LCRT þ adjuvant chemotherapy vs
total neoadjuvant treatment (TNT,
LCRT with sequential neoadjuvant
chemotherapy)
21% (LCRT þ adjuvant
chemotherapy)
36% (TNT). p , 0.001
AIO-12[54] 2019 Phase II RCT 311 (306
evaluable)
Induction chemotherapy (FOLFOX)




Not compared statistically (pick the
winner trial design).
ARISTOTLE[31]* 2020 Phase III RCT 564 LCRT vs LCRT with irinotecan 17.4% (LCRT)
20.2% (LCRT with irinotecan), p ¼
0.45
OPRA[57]* 2020 Phase III RCT 324 (307
evaluable)






Rates of organ preservation 43%
(induction), 58% (consolidation), p
¼ 0.01
RAPIDO[58,70,71] 2020 Phase III RCT 920 SCRT þ CAPOX/FOLFOX vs LCRT
and optional adjuvant
chemotherapy
27.7% (SCRT þ CAPOX/FOLFOX)
13.3% (LCRT þ optional adjuvant
chemotherapy), p , 0.001
PRODIGE 23[55]* 2020 Phase III RCT 231 LCRT þ 6 months adjuvant
chemotherapy vs mFOLFIRINOX
þ LCRT þ 3 months adjuvant
chemotherapy
11.7% (LCRT þ adjuvant
chemotherapy), 27.5%
(mFOLFIRINOX þ LCRT þ
adjuvant chemotherapy), p , 0.001
AIO: Arbesitsgemeinschaft Internistische Onkologie; CAPOX: capecitabine and oxaliplatin; FOLFOX: 5-fluorouracil and oxaliplatin; LCRT: long
course chemoradiation; mFOLFIRINOX: fluorouracil, irinotecan and oxaliplatin; OPRA: organ preservation in rectal adenocarcinoma; pCR:
pathological complete response; RAPIDO: rectal cancer and pre-operative induction therapy followed by dedicated operation; RCT: randomized
controlled trial; SCRT: short course radiotherapy; TNT: total neoadjuvant treatment; TROG: Trans-Tasman Radiation Oncology Group.
*Await full results.
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rationale to further investigate the use of immune
checkpoint inhibition neoadjuvantly for LARC. With
the primary disease in situ, there are differences in the
intrinsic tumor biology, as well as extrinsic microenvi-
ronment. Also, the combination of immunotherapy
with current neoadjuvant treatments of radiation and
chemotherapy potentially offer a therapeutic advantage
compared with using immune checkpoint inhibition
alone.
Favorable Tumor and Host Immune
Environment
In vivo and early trial evidence suggest that augment-
ed host antitumor immune responses are triggered when
immune checkpoint inhibition is given with the primary
tumor in situ. Liu et al[94] demonstrated stronger
expansion of tumor-specific CD8þ T cells in blood and
peripheral organs after neoadjuvant treatment with anti-
PD-1 and anti-CD137 therapies in a mouse breast cancer
model, compared with post-surgery. Half of mice treated
with this combination neoadjuvantly displayed long-
term survival, versus none in the adjuvant group. In the
clinical setting, Blank et al[95] reported results of a small,
early-phase, but translationally rich study, which treated
patients with stage III melanoma with combination
immune checkpoint inhibition in the neoadjuvant
versus adjuvant setting. Again, an increased expansion
of T-cell clones was observed preoperatively. Similar
results have also been observed in patients with
NSCLC[96] and bladder cancer.[97]
In the study by Blank et al,[95] the rate of grade 3/4
immune-related adverse events was much higher (90%
in both arms) compared with the expected incidence of
toxicity from studies using the same combination in
patients with stage IV melanoma.[98] This high level of
toxicity combined with the high level of pathological
responses seen in this study imply that, whether given
neoadjuvantly or adjuvantly, in patients with earlier-
stage disease there is less intrinsic suppression of the host
immune system. When using immune checkpoint
inhibition earlier in the disease trajectory, a lower dose
may therefore achieve the same efficacy as in the
metastatic setting and may be required to reduce
unacceptable levels of adverse events related to immune
stimulation.
In summary, this preclinical evidence and clinical
results from patients with colon cancer and other cancer
types provide an impetus to test neoadjuvant immuno-
therapy more extensively for treatment of LARC.
Immune Checkpoint Inhibition and
Radiation Treatment
Local effects
Traditional radiobiological dogma dictates that radia-
tion-induced tumor cell death is mediated via direct DNA
damage, free radical damage, and subsequent DNA
double-strand breaks, which if not repaired leads to
catastrophic death.[99,100] But it is increasingly recog-
nized that the tumor response also may be a result of the
effects on the immune microenvironment. Radiation
stimulates an antitumor immune response via several
mechanisms, such as increased antigen release and novel
peptide antigen expression on tumor cells, production of
interferon type 1,[101,102] complement activation, trans-
location of calretinin to the tumor cell surface, increased
expression of MHC class I,[103] expression of RAE-1,[104]
and release of damage-associated molecular patterns
such as HMGB1 and ATP leading to dendritic cell
recruitment.[105] The aggregate effect is to induce local,
tumor-specific T-cell responses. In turn, this may prime
the local tumor environment for treatment with immu-
notherapy.[106] Combination therapy has already
achieved success in the clinic for some solid tumor
types, such as NSCLC, bladder cancer, and melano-
ma.[107–111]
It remains unclear which radiotherapy fractionation
offers most synergy in combination with checkpoint
inhibition. Dovedi and colleagues[112] found similar
combinatorial activity from anti-PD-1 treatment and
radiotherapy across a range of radiotherapy fractionation
schedules. Others[113] demonstrated that a higher dose
per fraction (5 Gy per fraction) increased calreticulin
release, stimulating an increase in immune recognition
compared with more fractionated regimens. In contrast,
they showed that the optimum ratio of effector to T
regulatory cells occurs when a dose of 2 Gy per fraction is
used.
Several other variables, such as host, tumor, and
treatment-related factors influence responses,[114] in
particular, the scheduling of immunotherapy delivery
in relation to radiotherapy. For example, clinical trial
evidence from lung cancer has shown that survival is
increased when immune checkpoint inhibition is
delivered after radiation in the stage III setting.[110]
Preliminary findings from the VOLTAGE-A trial in
LARC[115] also showed encouraging results with sequen-
tial treatment. In contrast, preclinical evidence from
Dovedi et al[101] implies that earlier use of immuno-
therapy and specifically its combination with radiation
may lead to improved responses. Dovedi et al[101]
demonstrated that in vivo treatment with radiation
and concurrent anti-PD-L1 inhibition contributed to
overcome radiation-induced immune suppression, and
correlated with improved survival versus radiotherapy
alone. This improvement in survival was not observed
when sequential treatment (immune-checkpoint inhi-
bition at day 7 post-radiotherapy) was used. Analysis of
tumor-infiltrating CD8þ/CD4þ T cells at 24 hours after
the last dose of radiotherapy demonstrated an acute
increase in PD-1 expression, which was almost elimi-
nated by day 7. This suggests deletion or anergy of
tumor-specific CD8þ T cells by the later time point as
the mechanism for the differential response dependent
on the timing at which immune checkpoint inhibition
is delivered.
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In summary, radiotherapy alters the local tumor
immune microenvironment in a way that could be
exploited with immune checkpoint inhibition to pro-
duce a synergistic therapeutic response. More work is
required in both the preclinical and clinical settings to
understand the optimal timing for immune-checkpoint
delivery. Clinical evidence implies that improved re-
sponses are seen with sequential treatment, but preclin-
ical studies suggest that concomitant treatment may be
able to enhance responses further. Last, the binary
concept of ‘‘immune activation’’ may need to be
supplanted for a more qualitative measure of the type
of immune response elicited by different doses, fraction-
ations, and schedules.
Distant effects
The effects of immunotherapy-radiotherapy combina-
tions may not only occur at the local tumor level.
Although the immune-stimulatory effects of radiothera-
py are predominantly in the radiation field, several case
reports on tumor types such as melanoma[116] and
NSCLC[117] have demonstrated tumor regression distant
to the irradiated site when radiotherapy is combined
with immune checkpoint inhibition. These abscopal
effects (shrinkage of untreated metastases concurrently
with shrinkage of tumors within the area the localized
radiotherapy treatment) are rarely seen with radiother-
apy in isolation.[118] This can be explained in part by
considering how the immune system shapes cancer
growth. It is hypothesized that the host immune system
acts to control malignant growth initially via elimina-
tion, in which immunity functions as an extrinsic tumor
suppressor or later on, via an equilibrium state, whereby
the immune system holds remaining tumor cells in a
state of functional dormancy. Finally, tumors become
clinically apparent when they escape immune control, a
state in which the tumor has learned to evade the host
immunity. This three-stage process of elimination,
equilibrium, and escape is referred to as immunoedit-
ing.[119]
Radiotherapy can elicit a tumor-specific T-cell re-
sponse that, when combined with systemic immune
checkpoint inhibition, switches immunoediting by the
host immune system back into the elimination and
equilibrium phases. This may explain why disease sites
may regress even though they are distant to the primary
tumor that is being irradiated. [118] Supporting this
hypothesis, Dovedi et al[112] demonstrated that radio-
therapy alone increases T cells in an irradiated, but not
out-of-field tumor, and that similarly anti-PD-1 therapy
alone did not increase T-cell infiltration in either the
primary or distant tumor. The combination of radio-
therapy and anti-PD-1 therapy led to increased T-cell
infiltration in both the irradiated and out-of-field tumor
and an increase in T-cell diversity compared with non-
treated or anti-PD-1 monotherapy-treated mice. Se-
quential immune inhibition did not achieve the same
level of abscopal effect as concurrent treatment,
suggesting that exhaustion of tumor-infiltrating T cells
may occur after radiation unless the PD-1/PD-L1 axis is
blocked.
In conclusion, combination of radiotherapy and
immunotherapy has the potential to improve out-of-
field, distant micrometastatic disease by fundamentally
resetting the host–tumor immune interaction.
Immune Checkpoint Inhibition and
Chemotherapy
There has been concern that cytotoxic chemotherapy,
when used concomitantly with immunotherapy in the
neoadjuvant setting[120] may kill proliferating T cells and
dampen the induction of a broad T-cell response. Despite
this, Vincent et al[121] demonstrated that fluoropyrimi-
dine therapy is capable of eliminating immunosuppres-
sive myeloid-derived cells within the tumor
microenvironment, thereby enhancing host antitumor
immune responses. Furthermore, Tesniere et al[122]
showed that oxaliplatin elicits immunogenic cell death
in microsatellite stable colon tumors. Preclinical data
presented in abstract form (Dosset et al, unpublished
data, 2018) demonstrated that the combination of
fluoropyrimidine and oxaliplatin is capable of increasing
PD-L1 and CD8þ T-cell tumor infiltration in animal
models.[123] The combination treatment with anti-PD1
and FOLFOX therapy further improved tumor volume
reduction compared with chemotherapy or anti-PD1
monotherapy in CT26 and MC38 mice.[123] Evidence of
immune activation in patients with rectal cancer after
four cycles of FOLFOX has also been demonstrated and
quantified by increases in CD3, CD8, MHC1, and PD-L1
in rectal cancer biopsies,[124] with similar findings
reported by Teng et al[125] These data suggest, again,
that the received wisdom of ‘‘immune activation’’ as a
binary switch that is turned off by cytotoxic treatment
needs refining. Indeed, combining chemotherapy and
immunotherapy in CRC could lead to a synergistic
therapeutic effect at both the local and systemic levels.
Overall, evidence from CRC and other tumor types
provides a sound rationale to test immune checkpoint
inhibition in combination with radiotherapy and/or
chemotherapy. Although questions remain over which
dose, fractionation, and scheduling of chemo-radiother-
apy will produce optimal clinical responses in combina-
tion with immunotherapy, these uncertainties can only
be addressed with future, translationally rich clinical
studies.
CURRENT EVIDENCE AND ONGOING TRIALS
INVESTIGATING CHECKPOINT INHIBITORS
FOR RECTAL CANCER IN THE NEODJUVANT
SETTING
The intense interest in exploring these questions in
vivo has culminated in a wealth of clinical trials that are
either currently recruiting, or in set up, that use a named
checkpoint inhibitor in this context (Table 3). All of the
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LCRT) and one trial (PRIME-RT) investigates SCRT and
LCRT in two parallel treatment arms. In total, 11 of these
trials (50%) use systemic cytotoxic chemotherapy,
excluding concomitant radiosensitizing chemotherapy,
and one trial (CHINOREC) uses combination immuno-
therapy (nivolumab and ipilimumab). The most com-
mon endpoint is a measure of pathological or clinical
complete response (17/22, 77%) and several trials have
translational secondary endpoints. Two trials have the
neoadjuvant rectal score as the primary endpoint.
Although pCR is an outcome that has been very
commonly studied in previous neoadjuvant trials (see
Table 1), it has not been confirmed to correlate with
longer-term outcomes such as DFS or OS.[56] If these
trials (Table 3) demonstrate an improvement in pCR,
larger confirmatory studies will be required to under-
stand how this surrogate endpoint correlates with
meaningful differences in patient outcomes.
Given the potential overlapping adverse reactions with
combination treatment, the safety data from these trials
are eagerly awaited. To date, there have been encourag-
ing results from the VOLTAGE trial (NCT02948348; see
Table 2)[115] in which of 39 patients, no grade 4
nivolumab-related adverse events were recorded and all
severe immune-related adverse events had fully resolved
before surgery. Accounting for the one patient who
refused surgical resection following a complete clinical
response to treatment, 38 (97%) of 39 patients proceeded
to radical surgery.
Biomarkers of Response to Immune-
Checkpoint Inhibition
Currently, a potential predictive biomarker for re-
sponse to ICIs in metastatic CRC is MMR, as shown by
the KEYNOTE-016 trial,[81] but if validated, will be
relevant to a minority of rectal patients in the LARC
setting. Critical to the success of the outlined studies will
be the exploration of existing, and discovery of novel,
biomarkers of selection and response. The opportunity
to perform on-treatment biopsies of the primary tumor
and tumor microenvironment, as well as pathological
examination of the resection specimen taken at the time
of radical surgery must be grasped. Within the dMMR
population, many patients could be expected to not
respond or progress despite treatment with immune
checkpoint inhibitors. Prognostic (TILs, high frameshift
mutation load, and tumor mutational burden) and
predictive biomarkers (TILs, CD8þ as part of Immuno-
score) within this group of patients need exploring.
Loupakis et al[126] recently demonstrated, in a retrospec-
tive cohort study of patients with dMMR CRC treated
with ICIs, that higher levels of TILs correspond to higher
response rates and survival. PD-L1 has shown clear
utility as a biomarker to predict response to immuno-
therapy in other tumor types such as NSCLC,[127] but has
yet to demonstrate utility for patients with CRC. Neither
the KEYNOTE-016 trial, nor the Checkmate-142 trial
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and PD-L expression. Thus, prognostic and predictive
biomarkers for pMMR CRC tumors remain elusive. Those
under investigation include PD-L1, the Immunoscore,
POLE (DNA epsilon polymerase) mutations, major
histocompatibility complex class II expression, the
consensus molecular subtypes classification, and tumor
mutational burden.[92,128–130]
In LARC, there is conflicting retrospective evidence
regarding the prognostic value of PD-L1 expression
undergoing LCRT, with uncertainty as to whether it
represents a marker of improved[131] or poor[132] prog-
nosis. The Immunoscore is a CD3þ/CD8þ based method
of assessment (performed manually[133] or via image
analysis software[134,135]), which groups tumors accord-
ing to a semiquantitative grade based on presence of
high- or low-grade CD3þ/CD8þ cell assessments. The
Immunoscore has also been retrospectively analyzed in a
cohort of LARC[136] and showed that higher scores (I4
versus I0) correlate significantly with improved DFS and
OS in patients with operable rectal cancer and may also
predict for response to LCRT. The combination of PD-L1
status ( 1%) and CD8/Treg ratio (. 2.3) predicting for
response to neoadjuvant immune checkpoint inhibitor/
chemotherapy/radiotherapy combination treatment in
pMMR and dMMR LARC has emerged as an exciting
novel biomarker candidate, which requires further
exploration in a larger patient cohort.[115]
CONCLUSION
The current priorities for improving the outcomes of
LARC include reducing distant relapse rates while
simultaneously reducing the morbidity associated with
multimodality treatment. In this review, we have
summarized the key preclinical and clinical evidence
that underpins the potential role of ICIs in achieving
both of these goals. Using immune checkpoint inhibitors
in the neoadjuvant setting, where treatment compliance
is likely to be improved, could increase the proportion of
patients who respond and avoid surgical resection.
Although the gap between radiation and surgery exists
to allow for maturation of tumor response, it also
provides an obvious opportunity to deliver additional
treatments and an excellent platform for translational
research. There is good evidence from the metastatic
setting that some rectal cancers are responsive to
immune checkpoint inhibition. Moving immune-target-
ed treatment into the neoadjuvant setting, where there is
a higher burden of tumor antigens present to incite a
host immune response, is a logical progression. Available
preclinical evidence suggests that combining immuno-
therapy with radiation in particular leads to better
responses, but questions remain around the optimal
dose fractionation of radiation and scheduling of
immune checkpoint treatment. Finally, there is a high
unmet need to identify biomarkers of response to
radiation alone and radiotherapy/immune checkpoint
inhibitor combinations in patients with LARC. These are
imperative to understand which patients may or may
not benefit from treatment intensification and will be
critical to the success of this approach. There are a large
number of early clinical trials that are currently investi-
gating immune checkpoint inhibition in the treatment
of LARC, the results of which are eagerly awaited and will
shape the future landscape of immunotherapy research.
Acknowledgments
We thank Lorraine MacLeod at the Beatson West of
Scotland Cancer Centre, Greater Glasgow and Clyde
library service for her help in performing a literature
search.
References
1. World Cancer Research Fund. Colorectal Cancer Statis-
tics. 2020. Accessed Apr 25, 2020. www.wcrf.org/
dietandcancer/cancer-trends/colorectal-cancer-statistics
2. Cancer Research UK. Bowel cancer incidence statistics.
2020. Accessed Apr 25, 2020. www.cancerresearchuk.org/
health-professional/cancer-statistics/statistics-by-cancer-
type/bowel-cancer/incidence#heading-Four
3. McCall JL, Cox MR, Wattchow DA. Analysis of local
recurrence rates after surgery alone for rectal cancer. Int J
Colorectal Dis. 1995;10:126–132.
4. National Institute for Health and Care Excellence.
Colorectal Cancer Guidelines [NG151]. Published on Jan 29,
2020. www.nice.org.uk/guidance/ng151
5. National Comprehensive Cancer Network. NCCN Clinical
Practice Guidelines in Oncology (NCCN Guidelines) Rectal
Cancer Version 1.2021. Published on Dec 22, 2020. www.
nccn.org/professionals/physician_gls/pdf/rectal.pdf
6. Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative
chemoradiation versus radiation alone for stage II and III
resectable rectal cancer. Cochrane Database Syst Rev. 2009:
CD006041.
7. Glynne-Jones R, Hughes R. Critical appraisal of the ‘wait
and see’ approach in rectal cancer for clinical complete
responders after chemoradiation. Br J Surg. 2012;99:897–
909.
8. Probst CP, Becerra AZ, Aquina CT, et al. Extended
intervals after neoadjuvant therapy in locally advanced
rectal cancer: the key to improved tumor response and
potential organ preservation. J Am Coll Surg.
2015;221:430–440.
9. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Mi-
chalski W, Bebenek M, Kryj M. Long-term results of a
randomized trial comparing preoperative short-course
radiotherapy with preoperative conventionally fraction-
ated chemoradiation for rectal cancer. Br J Surg.
2006;93:1215–1223.
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